JMJesús M. González Mariscal

Jesús M. González Mariscal

*This is an algorithmically generated author record based on publicly available information.

Jesús M. González Mariscal has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Anja Loizaga-Velder

    Nierika Institute for Intercultural Medicine, Ocuilan, Mexico

    1 shared publication
  • Héctor Guzmán-González

    Servicios Clínicos. Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz (INPRFM), Mexico city, Mexico

    1 shared publication
  • Jesús Martín Torres-Valencia

    Universidad Autónoma del Estado de Hidalgo, State of Hidalgo, Mexico

    1 shared publication
  • José Luis Vega

    Servicios Clínicos. Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz (INPRFM), Mexico city, Mexico

    1 shared publication
  • María Eva González-Trujano

    Laboratorio de Neurofarmacología de Productos Naturales, Dirección de Investigaciones Biomédicas en Salud Mental, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calz. México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, Ciudad de México 14370, Mexico

    1 shared publication
  • Paulina E. Sosa‐Cortés

    Independent practioner, San Mateo Yoloxochitlan Oaxaca México

    1 shared publication

Latest Publications

  • A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder

    by Raul Escamilla, María Eva González-Trujano, Jesús M. González Mariscal, Jesús Martín Torres-Valencia, Héctor Guzmán-González, José Luis Vega, Anja Loizaga-Velder

    The pharmacological treatment of depression consists of taking antidepressant drugs for prolonged periods; its modest therapeutic effect can often be associated with significant adverse effects, while its discontinuation can lead to relapses. Psilocybin is today a novel and breakthrough therapy for major depression. It is a natural alkaloid in Psilocybe mushrooms, which are endemic to Mexico. Research on a larger scale is lacking in various populations, including the Mexican people. This proposal contemplates the experimental design of a preclinical (toxicity and pharmacological evaluation of an extract in mice) and clinical study by including the chemical analysis of a species of Psilocybe cubensis mushroom to characterize its main constituents. The clinical study will consider the safety evaluation by exploring tolerated doses of Psilocybe cubensis by measuring pharmacokinetic parameters after oral administration in healthy adults and an open trial on a sample of patients with major depressive disorder to assess the safety and efficacy of fully characterized Psilocybe cubensis in a two-single doses treatment, (with assisted psychotherapy), compared with the traditional care model at the Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz in Mexico City. This report presents the design of a research project with preclinical and clinical experimental components.


  • Insights for Modern Applications of Psilocybin Therapy from a Case Study of Traditional Mazatec Medicine

    by Jesús M. González‐Mariscal, Paulina E. Sosa‐Cortés

    The "people of knowledge" of traditional Mazatec medicine have preserved until today the ritual use of psilocybin mushrooms as part of their health care systems. The renewed interest in the effect of psilocybin on human consciousness for both therapeutic and recreational purposes usually obviates the historical and cultural background of indigenous peoples, as well as the legitimation of their practices and knowledge. In this article, through the case study of a foreign person who attended a Mazatec ritual specialist to participate in a ritual night ceremony known as velada, we show the importance of approaching research on psychoactive plants and mushrooms from a transdisciplinary and intercultural perspective, so that we can appreciate the profound complexity of the healing processes that take place in traditional indigenous contexts, as well as the limits of recreational uses or exclusively neopositivist and clinical approaches.